公开(公告)号：US20030224015A1

公开(公告)日：2003-12-04

申请号：US10384976

申请日：2003-03-10

发明人： Mary Katherine Hart ,  Julie Ann Wilson ,  Gene Garrard Olinger JR. ,  Michael Adam Bailey

IPC分类号： C12Q001/70 ,  C07H021/04 ,  A61K039/12 ,  C12N007/00 ,  C07K014/005

CPC分类号： C07K14/005 ,  A61K38/00 ,  A61K39/00 ,  A61K2039/5256 ,  A61K2039/53 ,  C12N7/00 ,  C12N15/86 ,  C12N2760/14022 ,  C12N2760/14122 ,  C12N2760/14134 ,  C12N2770/36123 ,  C12N2770/36143

摘要： Using CTL epitopes to the Ebola GP, NP, VP24, VP30, VP35 and VP40 virion proteins, a method and composition for use in inducing an immune response which is protective against infection with Ebola virus is described.

摘要翻译： 描述了使用针对埃博拉GP，NP，VP24，VP30，VP35和VP40病毒粒子蛋白的CTL表位，用于诱导免疫反应的方法和组合物，其针对埃博拉病毒感染。

公开(公告)号：US09290545B2

公开(公告)日：2016-03-22

申请号：US12864375

申请日：2010-07-23

申请人： Loren D. Walensky ,  Gregory H. Bird

发明人： Loren D. Walensky ,  Gregory H. Bird

IPC分类号： C07K14/005 ,  A61K38/16

CPC分类号： C07K14/005 ,  A61K38/162 ,  A61K39/145 ,  A61K39/155 ,  A61K39/21 ,  C07K16/1063 ,  C07K2317/76 ,  C12N2740/15022 ,  C12N2740/15034 ,  C12N2740/15071 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2740/16171 ,  C12N2740/16222 ,  C12N2740/16234 ,  C12N2740/16271 ,  C12N2760/14022 ,  C12N2760/14034 ,  C12N2760/14071 ,  C12N2760/16022 ,  C12N2760/16034 ,  C12N2760/16071 ,  C12N2760/18022 ,  C12N2760/18034 ,  C12N2760/18071 ,  C12N2760/18522 ,  C12N2760/18534 ,  C12N2760/18571 ,  C12N2760/18622 ,  C12N2760/18634 ,  C12N2760/18671

摘要： The invention provides compositions, kits and methods utilizing polypeptides having a viral alpha-helix heptad repeat domain in a stabilized α-helical structure (herein also referred to as SAH). The compositions are useful for treating and/or preventing viral infections. The invention is based, at least in part, on the result provided herein demonstrating that viral hydrocarbon stapled alpha helical peptides display excellent proteolytic, acid, and thermal stability, restore the native alpha-helical structure of the peptide, are highly effective in interfering with the viral fusogenic process, and possess superior pharmacokinetic properties compared to the corresponding unmodified peptides.

摘要翻译： 本发明提供了利用在稳定的α-螺旋结构（本文中也称为SAH）中具有病毒α-螺旋七肽重复结构域的多肽的组合物，试剂盒和方法。 该组合物可用于治疗和/或预防病毒感染。 本发明至少部分地基于本文提供的结果，证明病毒性碳氢化合物钉扎的α螺旋肽显示优异的蛋白水解，酸和热稳定性，恢复肽的天然α-螺旋结构，在干扰 病毒融合过程，并且与相应的未修饰的肽相比具有优异的药代动力学性质。

公开(公告)号：US20120156239A1

公开(公告)日：2012-06-21

申请号：US13349917

申请日：2012-01-13

申请人： Nancy Sullivan ,  Bimal Chakrabarti ,  Zhi-Yong Yang ,  Maria Grazia Pau ,  Jaap Goudsmit ,  Gary Nabel

发明人： Nancy Sullivan ,  Bimal Chakrabarti ,  Zhi-Yong Yang ,  Maria Grazia Pau ,  Jaap Goudsmit ,  Gary Nabel

IPC分类号： A61K39/12 ,  C12N7/01 ,  A61P31/14 ,  C12N15/63 ,  C12N15/40 ,  A61P37/04

CPC分类号： C12N15/86 ,  A61K39/12 ,  A61K2039/5156 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/53 ,  C07K14/005 ,  C12N2710/10343 ,  C12N2740/17022 ,  C12N2760/14022 ,  C12N2760/14134 ,  C12N2840/44

摘要： The invention is related to a nucleic acid molecule comprising a polynucleotide encoding a modified filovirus glycoprotein (GP) having at least one amino acid change located in a relatively conserved region of said GP that decreases in vitro cytotoxicity and retains immunogenicity when compared to in vitro cytotoxicity and immunogenicity of a wild type filovirus GP, and related modified filovirus GPs, plasmid DNAs, recombinant viruses, adenoviruses, pharmaceutical compositions, vaccine compositions, antibodies that are specifically reactive with the modified filovirus GPs, and related methods of making and using the same.

摘要翻译： 本发明涉及包含编码经修饰的病毒糖蛋白（GP）的多核苷酸的核酸分子，其具有位于所述GP的相对保守区域中的至少一个氨基酸改变，其降低体外细胞毒性并且与体外细胞毒性相比保留免疫原性 野生型病毒GP和相关修饰的病毒GP，质粒DNA，重组病毒，腺病毒，药物组合物，疫苗组合物，与修饰的病毒GP特异性反应的抗体的免疫原性及其制备和使用的相关方法。

公开(公告)号：US08101739B2

公开(公告)日：2012-01-24

申请号：US11662869

申请日：2005-09-27

申请人： Nancy Sullivan ,  Bimal Chakrabarti ,  Zhi-Yong Yang ,  Maria Grazia Pau ,  Jaap Goudsmit ,  Gary Nabel

发明人： Nancy Sullivan ,  Bimal Chakrabarti ,  Zhi-Yong Yang ,  Maria Grazia Pau ,  Jaap Goudsmit ,  Gary Nabel

IPC分类号： C07H21/04 ,  A61K39/12

CPC分类号： C12N15/86 ,  A61K39/12 ,  A61K2039/5156 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/53 ,  C07K14/005 ,  C12N2710/10343 ,  C12N2740/17022 ,  C12N2760/14022 ,  C12N2760/14134 ,  C12N2840/44

摘要： The invention is related to a nucleic acid molecule comprising a polynucleotide encoding a modified filovirus glycoprotein (GP) having at least one amino acid change located in a relatively conserved region of said GP that decreases in vitro cytotoxicity and retains immunogenicity when compared to in vitro cytotoxicity and immunogenicity of a wild type filovirus GP, and related modified filovirus GPs, plasmid DNAs, recombinant viruses, adenoviruses, pharmaceutical compositions, vaccine compositions, antibodies that are specifically reactive with the modified filovirus GPs, and related methods of making and using the same.

摘要翻译： 本发明涉及包含编码经修饰的病毒糖蛋白（GP）的多核苷酸的核酸分子，其具有位于所述GP的相对保守区域中的至少一个氨基酸改变，其降低体外细胞毒性并且与体外细胞毒性相比保留免疫原性 野生型病毒GP和相关修饰的病毒GP，质粒DNA，重组病毒，腺病毒，药物组合物，疫苗组合物，与修饰的病毒GP特异性反应的抗体的免疫原性及其制备和使用的相关方法。

公开(公告)号：US07736656B2

公开(公告)日：2010-06-15

申请号：US11068179

申请日：2005-02-28

申请人： Mary Kate Hart ,  Gene Garrard Olinger, Jr. ,  Michael Adam Bailey

发明人： Mary Kate Hart ,  Gene Garrard Olinger, Jr. ,  Michael Adam Bailey

IPC分类号： A61K39/12

CPC分类号： C07K14/005 ,  A61K38/00 ,  A61K39/00 ,  A61K39/12 ,  A61K2039/5256 ,  A61K2039/53 ,  C12N7/00 ,  C12N15/86 ,  C12N2760/14022 ,  C12N2760/14122 ,  C12N2760/14134 ,  C12N2760/14171 ,  C12N2770/36123 ,  C12N2770/36143

摘要： Using CTL epitopes to the Ebola GP, NP, VP24, VP30, VP35 and VP40 virion proteins, a method and composition for use in inducing an immune response which is protective against infection with Ebola virus is described.

摘要翻译： 描述了使用针对埃博拉GP，NP，VP24，VP30，VP35和VP40病毒粒子蛋白的CTL表位，用于诱导免疫反应的方法和组合物，其针对埃博拉病毒感染。

公开(公告)号：US07455994B2

公开(公告)日：2008-11-25

申请号：US11485158

申请日：2006-07-12

申请人： Michael C. Hevey ,  Diane I. Negley ,  Peter Pushko ,  Jonathan F. Smith ,  Alan L. Schmaljohn

发明人： Michael C. Hevey ,  Diane I. Negley ,  Peter Pushko ,  Jonathan F. Smith ,  Alan L. Schmaljohn

IPC分类号： C12N15/40

CPC分类号： C07K14/005 ,  A61K38/00 ,  A61K39/00 ,  A61K2039/5256 ,  A61K2039/53 ,  C07K16/10 ,  C12N7/00 ,  C12N15/86 ,  C12N2760/14022 ,  C12N2760/14222 ,  C12N2770/36021 ,  C12N2770/36122 ,  C12N2770/36123 ,  C12N2770/36143 ,  C12N2770/36162

摘要： Using the MBGV GP, NP, and virion proteins, a method and composition for use in inducing an immune response which is protective against infection with MBGV in nonhuman primates is described.

摘要翻译： 描述了使用MBGV GP，NP和病毒粒子蛋白，用于诱导免疫应答的方法和组合物，其在非人灵长类动物中防止MBGV感染。

公开(公告)号：US12116386B2

公开(公告)日：2024-10-15

申请号：US17573616

申请日：2022-01-11

申请人： The University of Queensland

发明人： Keith Joseph Chappell ,  Daniel Watterson ,  Paul Robert Young

IPC分类号： C07H21/02 ,  C07K14/16 ,  C07K19/00 ,  C12N15/10

CPC分类号： C07K14/16 ,  C07K19/00 ,  C12N15/1034 ,  C07K2317/55 ,  C07K2319/35 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2760/10022 ,  C12N2760/10034 ,  C12N2760/14022 ,  C12N2760/14034 ,  C12N2760/16122 ,  C12N2760/16134 ,  C12N2760/18022 ,  C12N2760/18034 ,  C12N2770/20022 ,  C12N2770/20034

摘要： Disclosed are chimeric polypeptides based on viral membrane fusion proteins. More particularly, the present invention discloses chimeric polypeptides that comprise a virion surface exposed portion of a viral fusion protein and a heterologous structure-stabilizing moiety, and to complexes of those chimeric polypeptides. The present invention also discloses the use of these complexes in compositions and methods for eliciting an immune response to a fusion protein of an enveloped virus, or complex of the fusion protein, and/or for treating or preventing an enveloped virus infection. The present invention further discloses the use of the heterologous structure-stabilizing moiety for oligomerizing heterologous molecules of interest.

公开(公告)号：US20180022790A1

公开(公告)日：2018-01-25

申请号：US15547379

申请日：2016-01-28

申请人： INTEGRATED BIOTHERAPEUTICS, INC. ,  AUBURN UNIVERSITY

发明人： Frederick Wayne HOLTSBERG ,  Mohammad Javad AMAN ,  Paul H. WALZ ,  Stephanie R. OSTROWSKI

IPC分类号： C07K16/10

CPC分类号： C07K16/10 ,  A61K39/12 ,  A61K39/395 ,  A61K39/39516 ,  A61K39/42 ,  A61K2039/505 ,  A61K2039/5258 ,  A61K2039/545 ,  C07K16/00 ,  C07K2317/20 ,  C07K2317/76 ,  C12N7/00 ,  C12N2760/14022 ,  C12N2760/14034 ,  C12N2760/14122 ,  C12N2760/14134 ,  C12N2760/14222 ,  C12N2760/14234

摘要： The disclosure provides a composition comprising immunoglobulin from an equine that has been hyper-immunized with a filovirus immunogen. The disclosure further provides methods of making such compositions and methods of using such compositions, e.g., for treating Ebola virus infection.

公开(公告)号：US20160237123A1

公开(公告)日：2016-08-18

申请号：US15146511

申请日：2016-05-04

申请人： Dana-Farber Cancer Institute, Inc.

发明人： Loren D. Walensky ,  Gregory H. Bird

IPC分类号： C07K14/005

CPC分类号： C07K14/005 ,  A61K38/162 ,  A61K39/145 ,  A61K39/155 ,  A61K39/21 ,  C07K16/1063 ,  C07K2317/76 ,  C12N2740/15022 ,  C12N2740/15034 ,  C12N2740/15071 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2740/16171 ,  C12N2740/16222 ,  C12N2740/16234 ,  C12N2740/16271 ,  C12N2760/14022 ,  C12N2760/14034 ,  C12N2760/14071 ,  C12N2760/16022 ,  C12N2760/16034 ,  C12N2760/16071 ,  C12N2760/18022 ,  C12N2760/18034 ,  C12N2760/18071 ,  C12N2760/18522 ,  C12N2760/18534 ,  C12N2760/18571 ,  C12N2760/18622 ,  C12N2760/18634 ,  C12N2760/18671

摘要： The invention provides compositions, kits and methods utilizing polypeptides having a viral alpha-helix heptad repeat domain in a stabilized α-helical structure (herein also referred to as SAH). The compositions are useful for treating and/or preventing viral infections. The invention is based, at least in part, on the result provided herein demonstrating that viral hydrocarbon stapled alpha helical peptides display excellent proteolytic, acid, and thermal stability, restore the native alpha-helical structure of the peptide, are highly effective in interfering with the viral fusogenic process, and possess superior pharmacokinetic properties compared to the corresponding unmodified peptides.

公开(公告)号：US20160152667A1

公开(公告)日：2016-06-02

申请号：US15019558

申请日：2016-02-09

申请人： Dana-Farber Cancer Institute, Inc.

发明人： Loren D. Walensky ,  Gregory H. Bird

IPC分类号： C07K14/005 ,  A61K39/145 ,  A61K39/155 ,  A61K39/21 ,  C07K16/10

CPC分类号： C07K14/005 ,  A61K38/162 ,  A61K39/145 ,  A61K39/155 ,  A61K39/21 ,  C07K16/1063 ,  C07K2317/76 ,  C12N2740/15022 ,  C12N2740/15034 ,  C12N2740/15071 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2740/16171 ,  C12N2740/16222 ,  C12N2740/16234 ,  C12N2740/16271 ,  C12N2760/14022 ,  C12N2760/14034 ,  C12N2760/14071 ,  C12N2760/16022 ,  C12N2760/16034 ,  C12N2760/16071 ,  C12N2760/18022 ,  C12N2760/18034 ,  C12N2760/18071 ,  C12N2760/18522 ,  C12N2760/18534 ,  C12N2760/18571 ,  C12N2760/18622 ,  C12N2760/18634 ,  C12N2760/18671

摘要： The invention provides compositions, kits and methods utilizing polypeptides having a viral alpha-helix heptad repeat domain in a stabilized α-helical structure (herein also referred to as SAH). The compositions are useful for treating and/or preventing viral infections. The invention is based, at least in part, on the result provided herein demonstrating that viral hydrocarbon stapled alpha helical peptides display excellent proteolytic, acid, and thermal stability, restore the native alpha-helical structure of the peptide, are highly effective in interfering with the viral fusogenic process, and possess superior pharmacokinetic properties compared to the corresponding unmodified peptides.

摘要翻译： 本发明提供了利用在稳定的α-螺旋结构（本文中也称为SAH）中具有病毒α-螺旋七肽重复结构域的多肽的组合物，试剂盒和方法。 该组合物可用于治疗和/或预防病毒感染。 本发明至少部分地基于本文提供的结果，证明病毒性碳氢化合物钉扎的α螺旋肽显示优异的蛋白水解，酸和热稳定性，恢复肽的天然α-螺旋结构，在干扰 病毒融合过程，并且与相应的未修饰的肽相比具有优异的药代动力学性质。